Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

Clinical Trial ID NCT00226473

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.	J Clin Oncol	1999	5.95
2	Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.	Ann Oncol	1997	4.69
3	Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy.	Lung Cancer	1999	1.15
4	Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).	Br J Cancer	2001	1.02
5	Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.	J Clin Oncol	1999	0.91
6	Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.	Melanoma Res	1999	0.75
7	Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.	Br J Cancer	2000	0.75